In this online, self-learning activity:
Major depressive disorder (MDD) is presently and has been a persistent major public health burden for several decades. Based on the National Comorbidity Survey data using the Composite International Diagnostic Interview, the estimated risk of MDD over any given 12-month period is 7.6%, with an estimated lifetime risk of 16.2%. Another estimate, from a recent wave of the National Health and Nutrition Examination Survey subdividing by gender indicates that 17.5% of men and 25.5% of women across all age groups overall report having experienced depressive symptoms in the past. Unfortunately, 58.8% of adults with symptoms classified as moderate and 36.9% of adults with symptoms classified as severe neither saw mental health professional nor received pharmacological treatment, suggesting a gap between present and optimal treatment of MDD.
Healthcare professionals specializing in: family medicine, internal medicine, mental health, neurology and psychiatry, or those who otherwise commonly care for patients with MDD or related psychiatric diseases.
This program is supported by an educational grant from Alkermes.
Release Date: April 05, 2018 -- Expiration Date: April 05, 2020
Faculty: Darin Signorelli, MD
Primer and updates on MDD’s epidemiology, neuropathophysiology, presentation, comorbidities, and psychosocial impact
Updates in MDD treatment and strategies for barriers to care
By the end of the session the participant will be able to:
ACCME Activity #201226540ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Darin Signorelli, M.D., Assistant Professor, Keck School of Medicine, USC, has no relevant conflicts of interest to disclose.
Faculty DOES plan to discuss off-label or investigational uses of a commercial product.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Alkermes
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Best Practices and Advances in Treatment Strategies in Bipolar Disorder Pharmacotherapy
Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices
Major Depressive Disorder (MDD): Updates from the American Psychiatric Association Annual Meeting (APA) 2017
Schizophrenia: Updates from the American Psychiatric Association Annual Meeting (APA) 2017